Exploiting cbf dependency in b-acute lymphoblastic leukaemia as a novel therapeutic approach

Leukaemia is the most common childhood cancer and acute lymphoblastic leukaemia (ALL) is responsible for a third of all childhood cancer deaths. Despite the overall good prognosis, failure to eradicate the disease leads to relapse in ∼20% of patients and survival rates for infants are less than 50%. There is therefore a clear unmet need for less toxic and more effective targeted treatments. ETV6-RUNX1 translocation is the first-hit event in ∼25% of B-ALLs, initiating a clinically silent pre-leukaemia in utero.

Source: Experimental Hematology - July 31, 2019 Category: Hematology Authors: Elitza Deltcheva, Jason Wray, Chela James, Charlotta Boiers, Jyoti Bikram Chettri, Simon Richardson, Anuradha Illendula, John Bushweller, Rachael Nimmo, Tariq Enver Tags: 3038 Source Type: research